MRFF – 2020 Antiviral Development for COVID-19 Grant Opportunity

Overview

Applications to this Medical Research Future Fund (MRFF) Coronavirus Research Response: 2020 Antiviral Development for COVID-19 grant opportunity must propose research to rapidly identify antiviral candidates targeting SARS-CoV-2 (new and repurposed) and accelerate promising effective treatments that can be made available to treat Australians infected with SARS-CoV-2. A competitive two stage funding process will be used: Stage 1: Funding of up to $3 million will be provided to support testing of up to 10 antiviral candidates for stability, safety and effectiveness against SARS-CoV-2 to demonstrate proof of concept. Stage 1 projects are to be completed within 9 months of commencement. Stage 2: Funding of up to $5 million will support acceleration of promising antiviral candidates from Stage 1 into clinical practice, enabling clinical trials in humans, progression through regulatory pathways and/or transition to commercialisation. Stage 2 projects are to be completed within 24 months of commencement. Applicants should note that the research funded by this grant opportunity is not intended to be used for vaccine development or respiratory medicine research for COVID-19. These issues are the subject of separate MRFF grant opportunities. This opportunity is supported by the Medical Research Future Fund (MRFF).